Pradofloxacin degrades or precipitates in liquid formulations, particularly when combined with NSAIDs or at higher concentrations required for parenteral administration.

Active pharmaceutical ingredients often trigger aversive gustatory responses in patients, leading to poor treatment compliance and rejection of oral solid dosages.

Elinzanetant formulations suffer from low drug loading and poor solubility which limits bioavailability in traditional solid dosage forms.

Unstable crystalline modifications or amorphous states lead to inconsistent drug dissolution and degraded shelf-life in solid oral formulations.